Full-Time

Director / Senior Director

Global Logistics, Warehousing and Trade Compliance

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops base editing–based precision medicines

Compensation Overview

$210k - $320k/yr

Cambridge, MA, USA + 1 more

More locations: Durham, NC, USA

In Person

Category
Operations & Logistics (3)
, ,
Required Skills
SAP Products
Requirements
  • Bachelor’s degree in Business, Supply Chain, Engineering, Life Sciences, or related field; MBA or Master’s degree preferred
  • 18+ years of progressive experience in global logistics, warehousing, supply chain, and/or trade compliance within biotech, pharmaceutical, or other highly regulated environments
  • Proven senior leadership experience managing complex global networks of internal operations and external partners (CMOs, CDMOs, 3PLs)
  • Working knowledge of global trade compliance regulations, including U.S. Customs and relevant international authorities; experience with permits, licenses, duties, VAT, sanctions, and duty savings strategies
  • Demonstrated expertise in pharmaceutical cold chain logistics (ambient, refrigerated, frozen, ultra-low temperature) across R&D, clinical, and commercial programs
  • Strong strategic and operational leadership skills, with the ability to influence cross-functional and matrixed stakeholders globally
  • Excellent analytical, communication, and decision-making skills in high-complexity environments
  • Financial acumen including budgeting, cost control, and KPI management
  • Experience with ERP systems (SAP preferred) and electronic Quality Management Systems
  • Travel up to 20% and onsite daily work with flexible schedule during peak times; must be able to work onsite daily and support critical operations outside normal hours
Responsibilities
  • Provide operational leadership for global logistics for R&D, Clinical, and Commercial shipments; serve as subject matter expert for ambient, low-temperature, and ultra-low-temperature cold chain systems, including shipping systems qualification and lane validation, in support of CMC development and commercialization
  • Lead internal warehouse operations and the global third-party logistics network supporting storage, inventory management, kitting, and production support for critical raw materials, drug substance, and drug product; ensure inventory accuracy, material availability, and scalable warehouse capabilities aligned with clinical and commercial demand
  • Act as the enterprise risk leader for global trade compliance, ensuring compliance with international, federal, and state import/export laws and regulations; lead development and governance of compliant trade processes across North America, Europe, and Asia-Pacific; serve as primary interface with customs brokers, government agencies, and external auditors; support Market Access team for any commercial trade or channel distribution aspects
  • Develop and execute global logistics, warehousing, and trade compliance strategy to support R&D, clinical trials, and commercial operations; establish long-term vision for a flexible, scalable global distribution and storage network; influence enterprise and site-level supply chain strategies; build and develop high-performing teams
  • Provide operational leadership for global distribution, including domestic and international shipments from internal sites and external partners; lead shipping operations ensuring on-time, in-full delivery and patient-centric execution
  • Own cold chain strategy and execution, including qualification, validation, monitoring, and continuous improvement of shipping lanes and systems
  • Lead internal and external warehousing operations, including inventory control, materials management, kitting, and production support; ensure no disruption to production schedules while proactively mitigating supply risks; drive inventory optimization, accuracy, and visibility using ERP and digital tools
  • Create, lead, and chair the Trade Compliance Committee; develop and maintain a robust global import/export compliance framework including permits, licenses, valuation, duties, VAT, sanctions, HTS classification, country of origin, and applicable Tariffs/Free trade agreements
  • Serve as primary respondent to regulatory agency inquiries; investigate issues, develop corrective strategies, and ensure timely, compliant responses
  • Lead duty savings and optimization strategies in collaboration with Finance and Supply Chain while maintaining full regulatory compliance
  • Establish and monitor KPIs across logistics, warehousing, and trade compliance with data-driven reporting
  • Manage operating budgets, capital expenditures, and cost optimization initiatives
  • Drive automation, digitalization, and process improvements to enhance efficiency, scalability, and compliance
  • Champion lean principles, continuous improvement, and right-first-time execution across the organization
  • Build and maintain strong partnerships with Legal, Finance, Clinical, Commercial, Quality, Manufacturing, Procurement, IT, and HR; represent the company with customs authorities, regulatory agencies, industry groups, and external counsel; participate in global forums to influence policy, standardization, and best practices across the supply chain network
Desired Qualifications
  • MBA or Master’s degree preferred
  • Relevant certifications or formal trade compliance training are preferred (e.g., Customs, Export Compliance, APICS, Hazardous Materials)
  • Experience with or knowledge of governance frameworks or trade compliance programs beyond baseline requirements

Beam Therapeutics uses base editing to develop precision genetic medicines aimed at correcting disease-causing mutations. It focuses on R&D and collaborates with pharmaceutical companies and research institutions to fund and advance therapies, earning revenue through partnerships, licensing, upfront and milestone payments, and royalties. The company targets genetic disorders such as sickle cell disease with the goal of delivering lifelong cures, differentiating itself through its emphasis on durable genetic remedies and a science-driven, values-led culture.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • BEAM-302 achieves clinical proof-of-concept in alpha-1 antitrypsin deficiency Phase 1/2 trial.
  • $500M Sixth Street credit facility funds risto-cel sickle cell launch by 2027.
  • BEACON trial data for BEAM-101 in 17 sickle cell patients presented at EHA2025.

What critics are saying

  • CRISPR Therapeutics' Casgevy captures 70% sickle cell market share since December 2024.
  • Busulfan conditioning toxicity halts BEAM-101 trial per EHA2025 data.
  • Prime Medicine's prime editing outperforms base editing in AATD models per October 2025.

What makes Beam Therapeutics unique

  • Beam's base editors precisely convert single DNA bases without double-strand breaks.
  • Proprietary cytosine and adenine editors target point mutations in genetic diseases.
  • Founded in 2017 by Harvard base editing pioneers for precision genetic medicines.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Beam Therapeutics who can refer or advise you

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
Yahoo Finance
Apr 11th, 2026
Beam Therapeutics CEO sells 30,000 shares worth $739K under trading plan

Beam Therapeutics CEO John Evans sold 30,078 shares on 1 April 2026 for approximately $739,000, according to an SEC Form 4 filing. The shares were sold at around $24.58 each under a pre-established Rule 10b5-1 trading plan. This sale is smaller than Evans' recent average of 45,200 shares per transaction and represents his smallest open-market sale in his last four disclosed transactions. Following the sale, Evans retains 1,047,205 direct shares and 103,000 indirect shares, maintaining direct ownership of 1.03% of outstanding shares. Beam Therapeutics, valued at $2.79 billion, develops precision genetic medicines using base editing technology, focusing on treatments for sickle cell disease, beta thalassemia and other rare genetic disorders.

pharmaphorum
Apr 10th, 2026
Chinese trial backs base-editing drug for thalassaemia.

Chinese trial backs base-editing drug for thalassaemia. digitale.de A landmark study in China has shown that a base-editing therapy developed by CorrectSequence Therapeutics achieved stellar results in patients with the severe blood disorder beta-thalassaemia. The ex vivo therapy, CS-101, has been tested in an investigator-led trial in five patients with transfusion-dependent beta-thalassemia who received autologous CD34 stem cells modified with the base editor to reactivate the production of a foetal form of haemoglobin. In beta-thalassaemia, mutations in the beta-globin gene mean that patients have deficient production of the adult form of haemoglobin. In severe cases, they have to have blood transfusions every two to five weeks to survive, a burdensome treatment that also places them at risk of complications like iron overload and infections. In the trial, all five patients were able to discontinue transfusions after a single infusion of CS-101-modified stem cells, with rapid and sustained increases in haemoglobin levels over three months of follow-up. Remarkably, patients became transfusion-independent within an average of just 16 days, according to the researchers, who have published their findings in the journal Nature. Shanghai-based CorrectSequence is one of the pioneers of the base-editing approach to gene-editing, which can be used to convert one nucleotide base into another without cutting both strands of DNA, unlike other technologies like CRISPR/Cas9. Theoretically, base-editing should be more accurate and have a reduced risk of off-target changes that could cause side effects. CorrectSequence said that, compared to CRISPR-based therapies for beta-thalassaemia, CS-101 demonstrated "faster activation of foetal haemoglobin, more rapid hematopoietic recovery, and earlier restoration of normal haemoglobin levels." The only gene-editing therapy approved for beta-thalassaemia at present is Vertex Pharma's CRISPR-based Casgevy (exagamglogene autotemcel), which has been cleared in the US and Europe for patients aged 12 and older with transfusion-dependent beta-thalassaemia who lack a suitable donor for stem cell transplant. Donor stem cell transplantation was the only curative option for patients for many years, but its use is limited by donor availability, the risk of immune rejection, and high treatment costs, said CorrectSequence. The company thinks CS-101 - which has now been used to treat around 20 patients in the US and internationally - has the potential to become the world's first approved base-editing therapy. Last year, it also reported encouraging clinical results in a patient with chylomicronaemia treated with its CS-121 base editor targeting the APOC3 gene. Other companies working on base-editing technologies include Beam Therapeutics of the US, which is developing a similarly acting ex vivo therapy for sickle cell disease (SCD), called ristoglogene autogetemcel, that showed efficacy in a phase 1/2 trial published in the New England Journal of Medicine earlier this month and could be submitted for FDA approval before the end of the year.

MarketScreener
Feb 24th, 2026
Beam Therapeutics secures $500M credit facility with Sixth Street for sickle cell treatment launch

Beam Therapeutics has secured a $500 million senior secured credit facility with Sixth Street to support the anticipated launch of ristoglogene autogetemcel (risto-cel) for sickle cell disease. The agreement includes $100 million funded at close, up to $300 million available upon clinical, regulatory and commercial milestones, and an additional $100 million at Beam's option. The facility has a seven-year term maturing in early 2033, with an annual interest rate of approximately 10% based on SOFR. No scheduled amortization payments are required, with all principal due at maturity. Beam expects to draw at least $200 million under the facility. The financing provides non-dilutive capital to support risto-cel's commercialisation whilst allowing Beam to direct resources towards pipeline growth and developing precision genetic medicines.

Sahm Capital
Dec 19th, 2025
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Beam Therapeutics to present at 44th Annual J.P. Morgan Healthcare Conference. Beam Therapeutics +1.33% CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT in San Francisco. The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Holly Manning Beam Therapeutics [email protected] This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

NetworkNewsWire
May 23rd, 2025
Networknewsbreaks - Beam Therapeutics Inc. (Nasdaq: Beam) To Present New Sickle Cell Data From Beacon Trial At Eha2025

Beam Therapeutics (NASDAQ: BEAM), a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated data from its BEACON Phase 1/2 trial of BEAM-101 at the European Hematology Association 2025 Congress, June 12-15 in Milan. BEAM-101 is an investigational, one-time ex vivo cell therapy targeting severe vaso-occlusive crises in sickle cell disease (SCD). The new data, covering safety and efficacy outcomes in 17 patients, will be highlighted during multiple poster sessions on June 13, underscoring BEAM-101’s potential to provide a durable treatment by addressing the root cause of SCD. Additional presentations will explore biomarkers, manufacturing advances, and red blood cell health post-treatment. Beam will also host a webcast on June 13 at 4:00 p.m. ET to review EHA highlights. To view the full press release, visit https://nnw.fm/taUAe About Beam Therapeutics Beam Therapeutics (NASDAQ: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines